How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,677 results for

Thyroid Function Summary

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Long Non Coding RNA HOTAIR and Midkine as Biomarkers in Thyroid Cancer

See Sponsor: Assiut University Information provided by (Responsible Party): Hala Saleh Abdelghafour, Assiut University Study Details Study Description Go to Brief Summary: Thyroid cancer is the most prevalent endocrine malignancy.Papillary thyroid carcinomas and follicular thyroid carcinomas account for 95% of all thyroid cancer cases. They are clinically classified as well-differentiated thyroid carcinomas due to their biological behavior resembling normal follicular cells and good responsiveness (...) or disease Intervention/treatment Thyroid Cancer Other: complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body specific test Real time polymerase chain reaction Detailed Description: Thyroid cancer is the most prevalent endocrine malignancy.Papillary thyroid carcinomas and follicular thyroid carcinomas account for 95% of all thyroid cancer cases. They are clinically classified as well-differentiated thyroid

2018 Clinical Trials

82. A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.

First Posted : March 19, 2018 Last Update Posted : January 10, 2019 See Sponsor: AHS Cancer Control Alberta Collaborator: Alberta Cancer Foundation Information provided by (Responsible Party): AHS Cancer Control Alberta Study Details Study Description Go to Brief Summary: Thyroid cancers that have spread beyond the neck are not curable. About 30,000 people worldwide die from thyroid cancer every year. Usually, thyroid cancers get worse because the cancer cells become more and more abnormal through (...) and thyroid cancer dedifferentiation. PDGFRα helps cancer progression and lowers the ability of sodium iodine symporters to move radioiodine into cells where it would normal act to kill the cancer cells. PDGFRα therefore makes thyroid cells resistant to radioactive iodine. Imatinib is an anti-cancer drug that blocks PDGFRα function. It has been used for many years to treat other cancers such as leukemia. The investigators who wrote this study believe that, base on laboratory testing, if thyroid cancer

2018 Clinical Trials

83. Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil

: December 17, 2018 Sponsor: Eisai Inc. Information provided by (Responsible Party): Eisai Inc. Study Details Study Description Go to Brief Summary: This is an Expanded Access Program to make lenvatinib available to participants with radioiodine-refractory differentiated thyroid cancer in Brazil. Participants who have no other treatment options available, and who, in the opinion and clinical judgment of the treating physician, would benefit from treatment with lenvatinib will be enrolled (...) Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2018 Clinical Trials

84. Efficacy of a Spirulina Supplement for Amelioration of Benign ThYroid Nodules

: June 5, 2018 See Sponsor: Fundatia Bio-Forum Information provided by (Responsible Party): Fundatia Bio-Forum Study Details Study Description Go to Brief Summary: Clinical trial with a double-blind, placebo-controlled, crossover design; enrolls approximately 30 euthyroid patients with benign thyroid nodules, who will receive for 6 weeks a spirulina-based supplement, and for another 6 weeks placebo. Thyroid ecography will be performed three times for each patient, and blood tests including TSH, free (...) levels of the molecules which reflect thyroid function Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 30 participants Allocation: Non-Randomized Intervention Model: Crossover Assignment Masking: Double (Participant, Care Provider) Primary Purpose: Treatment Official Title: Evaluation of the Efficacy of a Supplement With Spirulina for Amelioration of Benign Thyroid Nodules Actual Study Start Date : May 15, 2018 Estimated

2018 Clinical Trials

85. Effect of Reversed Tracking Method for Identification of EBSLN in Thyroid Surgery

Update Posted : November 9, 2018 See Sponsor: Fujian Medical University Information provided by (Responsible Party): Bo Wang,MD, Fujian Medical University Study Details Study Description Go to Brief Summary: The feasibility and effectiveness of Reversed Tracking Method for the identification and protection of extralaryngeal nerve branches in thyroid surgery were analyzed. Evidence-based medical evidence was used to evaluate the importance of EBSLN recognition and protection in thyroid surgery (...) Effect of Reversed Tracking Method for Identification of EBSLN in Thyroid Surgery Effect of Reversed Tracking Method for Identification of EBSLN in Thyroid Surgery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding

2018 Clinical Trials

86. Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas

Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results (...) information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas (LENVOS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators

2018 Clinical Trials

87. Downregulation of miR-486-5p in papillary thyroid carcinoma tissue: A study based on microarray and miRNA sequencing Full Text available with Trip Pro

Downregulation of miR-486-5p in papillary thyroid carcinoma tissue: A study based on microarray and miRNA sequencing Abnormal expression of microRNA (miR) is associated with the occurrence and progression of various types of cancers, including papillary thyroid carcinoma (PTC). In the present study, the aim was to explore miR‑486‑5p expression and its role in PTC, as well as to investigate the biological function of its potential target genes. The expression levels of miR‑486‑5p and its (...) clinicopathological significance were examined in 507 PTC and 59 normal thyroid samples via The Cancer Genome Atlas (TCGA). Subsequently, the results were validated using data from Gene Expression Omnibus (GEO) and ArrayExpress. Receiver operating characteristic and summary receiver operating characteristic curves were used to assess the ability of miR‑486‑5p in distinguishing PTC from normal tissue. Furthermore, potential miR‑486‑5p mRNA targets were identified using 12 prediction tools and enrichment analysis

2018 Molecular medicine reports

88. LncRNA SNHG15 acts as a ceRNA to regulate YAP1-Hippo signaling pathway by sponging miR-200a-3p in papillary thyroid carcinoma Full Text available with Trip Pro

miR-200a-3p. Moreover, results of gain-of-function assays validated the anti-oncogenic function of miR-200a-3p in papillary thyroid carcinoma. Finally, results of rescue assays validated the function of SNHG15-miR-200a-3p-YAP1 axis in papillary thyroid carcinoma. YAP1 is known as an oncogene and a core factor of Hippo pathway. Here, we demonstrated that SNHG15 inactivated Hippo signaling pathway in papillary thyroid carcinoma. In summary, our findings demonstrated that SNHG15 serves (...) expression of SNHG15 in human papillary thyroid carcinoma tissues and cell lines. Moreover, Kaplan-Meier method was utilized to analyze the internal relevance between SNHG15 expression and overall survival rate of patients with papillary thyroid carcinoma. Loss-of-function assays were designed and conducted to determine the inhibitory effects of silenced SNHG15 on the cell growth and migration in papillary thyroid carcinoma. The mechanical investigation indicated that SNHG15 upregulated YAP1 by sponging

2018 Cell death & disease

89. Reference intervals of thyroid hormones in Khartoum, Sudan Full Text available with Trip Pro

Reference intervals of thyroid hormones in Khartoum, Sudan This study aimed to establish the reference intervals (RIs) of thyroid function test among the adult Sudanese population in Khartoum, Sudan. A multi-stage survey stratified sampling method was used. Total triiodothyronine (TT3), total thyroxine (TT4) level and thyroid stimulating hormone (TSH) levels were measured using radioimmunoassay gamma counter (Riostad, Germany) to determine the reference intervals.A total of 390 adults aged 20 (...) increase with age. In summary the RIs for TSH, TT4 and TT3 in this setting were different from the levels provided by the manufacturers. A significant different was observed in TSH and FT4 when considering gender issue. The RIs were not different in the different age groups except for FT4.

2018 BMC research notes

90. LncRNA HCP5 promotes follicular thyroid carcinoma progression via miRNAs sponge Full Text available with Trip Pro

LncRNA HCP5 promotes follicular thyroid carcinoma progression via miRNAs sponge Long non-coding RNAs (lncRNAs), which are important functional regulators in cancer, have received increased attention in recent years. In this study, next-generation sequencing technology was used to identify aberrantly expressed lncRNAs in follicular thyroid carcinoma (FTC). The long non-coding RNA-HLA complex P5 (HCP5) was found to be overexpressed in FTC. The results of the qPCR analysis were consistent (...) that the expression of HCP5 was elevated and was correlated with the levels of ST6GAL2 in FTC tissues and cells. Mechanistic experiments showed that HCP5 functions as a competing endogenous RNA (ceRNA) and acts as a sponge for miR-22-3p, miR-186-5p and miR-216a-5p, which activates ST6GAL2. In summary, our study revealed that HCP5 is a tumour regulator in the development of FTC and that it may contribute to improvement of FTC diagnosis and therapy.

2018 Cell death & disease

91. Study of the Feasibility of Radiofrequency Ablation of Benign Thyroid Nodules

Update Posted : December 3, 2018 See Sponsor: University Hospital, Toulouse Information provided by (Responsible Party): University Hospital, Toulouse Study Details Study Description Go to Brief Summary: The purpose of the present protocol is to evaluate the response rate to treatment of these symptomatic benign nodules with radiofrequency as an alternative to surgical treatment. This thyroid nodules ablation with radiofrequency will be directed by a single percutaneous procedure guided by ultrasound (...) . The procedure includes an ultrasound with percutaneously radiofrequency ablation of benign thyroid nodule. Clinical and ultrasonographic monitoring will last a year with consultations at 2 weeks (consultation only), 3 months, 6 months and 1 year (consultation, ultrasound TSH). The success of this procedure will be controlled with 3 successive ultrasounds the following year. The expected results are a decrease in the size of the nodule by at least 50% and a reduction in the functional and aesthetic

2018 Clinical Trials

92. Alterations in Quality of Life After Thyroidectomy for Benign Thyroid Disease

, 2018 See Sponsor: Aristotle University Of Thessaloniki Information provided by (Responsible Party): Papavramidis Theodossis, Aristotle University Of Thessaloniki Study Details Study Description Go to Brief Summary: To detect any changes in Quality of Life in patients with benign thyroid diseases who undergo thyroidectomy compared to patients with benign thyroid diseases and conservative treatment and healthy subjects. Condition or disease Intervention/treatment Benign Thyroid Nodule Quality of Life (...) Frame: 2 years ] Correlation of alterations in Quality of Life after thyroidectomy for benign thyroid disease with secondary characteristics of the patients ( eg age, thyroid autoimmunity, thyroid function, Vitamin D levels) Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your

2018 Clinical Trials

93. A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

. ClinicalTrials.gov Identifier: NCT03573960 Recruitment Status : Recruiting First Posted : June 29, 2018 Last Update Posted : March 11, 2019 See Sponsor: Eisai Inc. Information provided by (Responsible Party): Eisai Inc. Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the safety of lenvatinib in participants with recurrent, metastatic radio-iodine refractory differentiated thyroid cancer (DTC). Condition or disease Intervention/treatment Phase Thyroid Neoplasms Drug (...) A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2018 Clinical Trials

94. Thyroid Hormone Replacement for Subclinical Hypothyroidism and Dyslipidemia in ASCVD

, the percentage of those who did not reach the target of lipid-lowering therapy (LDL-C>1.8mmol/L) is usually higher than that in population with normal thyroid function. The present study aims to randomly compare two lipid-lowering therapeutic strategies (statins only vs. statins combined with thyroid hormone supplement). Condition or disease Intervention/treatment Phase Dyslipidemia Subclinical hypothyroïdism Statin ASCVD Drug: Pitavastatin and placebo Drug: Pitavastatin and levothyroxine Not Applicable (...) is 12.5ug. The dosage of levothyroxine will be regulated according to thyroid function test every 2-3 weeks. The regulation of pitavastatin dosage is same as the monotherapy group. Outcome Measures Go to Primary Outcome Measures : Change of LDL-C levels [ Time Frame: Baseline and 6-month. ] Absolute change value of serum LDL-C levels between the baseline and 6-month assessment. Secondary Outcome Measures : Changes of non-LDL lipid levels (TC, TG, HDL-C, non-HDL-C) [ Time Frame: Baseline and 6-month

2018 Clinical Trials

95. Study on Application of Suturing Parathyroid Markers in Thyroid Cancer Surgery

, 2018 See Sponsor: Bo Wang,MD Information provided by (Responsible Party): Bo Wang,MD, Fujian Medical University Study Details Study Description Go to Brief Summary: To study the protective effect of suture parathyroid marker method on the function of parathyroid gland in thyroid cancer surgery Condition or disease Intervention/treatment Phase Thyroid Cancer Hypoparathyroidism Marker; Structural Complication of Surgical Procedure Parathyroid Function Low Adverse Event Procedure: The suture marks (...) Study on Application of Suturing Parathyroid Markers in Thyroid Cancer Surgery Study on Application of Suturing Parathyroid Markers in Thyroid Cancer Surgery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2018 Clinical Trials

96. Thyroid Dysfunction in Female Patients With Acne Vulgaris: [ Relation to Other Variables ]

androgens and steroids are one of multiple factors provoked to be involved in pathogenesis of acne . Thyroid hormones have steroid like action that have many regulatory functions in many body organ functions including skin and pilosebaceous unit. Furthermore, subtle thyroid dysfunction was shown to have a role in many disease conditions. Thyroid hormone action on sebaceous glands is unclear. In hypothyroid states, sebocytes exhibit reduced rates of secretion that increases with thyroxine administration (...) , fast method for the determination of severity of acne, and it requires no special equipment and is relatively cost-effective. Its personal and interpersonal differences is low and it was first used by Doshi and his colleagues in 1997 in USA . To the best of knowledge, little is published about thyroid dysfunction in acne female patients of different age categories and correlating thyroid function with other important patient and acne variables as body mass index (BMI) , age (starting from 16 years

2018 Clinical Trials

97. Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Co.,Ltd Information provided by (Responsible Party): Suzhou Zelgen Biopharmaceuticals Co.,Ltd Study Details Study Description Go to Brief Summary: Donafenib for advanced 131I-refractory/resistant differentiated thyroid cancer(DTC). Condition or disease Intervention/treatment Phase Differentiated Thyroid Cancer Drug: Donafenib Drug: Placebo Phase 3 Detailed Description: This phase 3 study of donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases (...) Donafenib in 131I-Refractory Differentiated Thyroid Cancer Donafenib in 131I-Refractory Differentiated Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Donafenib in 131I-Refractory

2018 Clinical Trials

98. Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Posted : February 8, 2019 See Sponsor: H. Lee Moffitt Cancer Center and Research Institute Information provided by (Responsible Party): H. Lee Moffitt Cancer Center and Research Institute Study Details Study Description Go to Brief Summary: Participants will have been diagnosed with advanced progressive thyroid cancer and are about to start treatment with a tyrosine kinase inhibitor (TKI). The purpose of this study is to evaluate the efficacy and tolerability of tyrosine kinase inhibitor therapy (...) Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding

2018 Clinical Trials

99. Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma

Recruitment Status : Not yet recruiting First Posted : August 17, 2018 Last Update Posted : August 17, 2018 See Sponsor: Assistance Publique Hopitaux De Marseille Information provided by (Responsible Party): Assistance Publique Hopitaux De Marseille Study Details Study Description Go to Brief Summary: Medullary thyroid carcinoma (MTC) develops at the expense of calcitonin cells and is often characterized by lymph node metastases and sometimes visceral metastases. Improvement of preoperative diagnosis (...) Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2018 Clinical Trials

100. Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial

. Patients with intolerable toxicity to MKIs that meet the prior inclusion criteria and experience disease progression by RECIST v1.1 after stopping therapy may be included. Cohort 3: Patients with locally advanced or metastatic anaplastic thyroid cancer regardless of prior therapy. No prior therapy with immune check point inhibitors is allowed. No limitation of number of prior therapies. Life expectancy >3 months Adequate normal organ and marrow function as defined below: a) Haemoglobin ≥9.0 g/dL. b (...) Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>